Abbvie Stock Forecast 2024. >$17b in 2027 ($11.5b from pso/psa; 184.49 0.00 0.00% the 24 analysts offering 1 year price forecasts for abbv have a max estimate of — and a min estimate of —.
The numbers are impressive considering abbvie guided 2024 adjusted eps to $11.37 to $11.57 when excluding $0.32 in dilutive impact from the immunogen ( imgn) and cerevel therapeutics ( cere). Provides 2024 adjusted diluted eps guidance range of $11.05 to $11.25;
On Average, 9 Wall Street Analysts Forecast Abbv's Revenue For 2025 To Be $103,153,653,417,145, With.
The numbers are impressive considering abbvie guided 2024 adjusted eps to $11.37 to $11.57 when excluding $0.32 in dilutive impact from the immunogen ( imgn) and cerevel therapeutics ( cere).
Our Forecast For Abbv Stock Price In 2024 Now Indicates An Average Price Target Of $143.79 With A High Forecast Of $158.10 And A Low Forecast Of $129.47.
>$17b in 2027 ($11.5b from pso/psa;
Adjusted Diluted Eps Of $11.11, A Decrease Of 19.3 Percent;
Images References :
The Company's 2024 Adjusted Diluted Eps Guidance Excludes Any Impact From.
According to the issued ratings of 13 analysts in the last year, the consensus rating for abbvie stock is moderate buy based on the current 3 hold ratings and 10 buy ratings for abbv.
The Company's 2024 Adjusted Diluted Eps Guidance Excludes Any Impact From.
Reported eps is $2.31, expectations were $2.26.
These Results Include An Unfavorable Impact Of $0.42 Per Share Related To 2023 Acquired Ipr&Amp;D And Milestones Expense.